Day One Biopharmaceuticals
DAWN
DAWN was delisted on the 22nd of April, 2026.
164 hedge funds and large institutions have $1.19B invested in Day One Biopharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 62 increasing their positions, 39 reducing their positions, and 33 closing their positions.
59% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 39
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
3% less first-time investments, than exits
New positions opened: 32 | Existing positions closed: 33
1% less funds holding
Funds holding: 166 → 164 (-2)
7% less capital invested
Capital invested by funds: $1.28B → $1.19B (-$96M)
11.94% less ownership
Funds ownership: 104.89% → 92.95% (-12%)
38% less call options, than puts
Call options by funds: $2.08M | Put options by funds: $3.36M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$76.2M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
+$35M |
| 3 |
BlackRock
New York
|
+$20.1M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$15.3M |
| 5 |
ECM
Estuary Capital Management
Wayzata,
Minnesota
|
+$13.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
-$35.6M |
| 2 |
MC
Maverick Capital
Dallas,
Texas
|
-$29.4M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$29.4M |
| 4 |
Goldman Sachs
New York
|
-$18.1M |
| 5 |
VPC
Vestal Point Capital
New York
|
-$14.7M |
DAWN Hedge Fund Activity: Q4 2024 in Review
164 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Day One Biopharmaceuticals (DAWN) for Q4 2024, worth a combined $1.19B — down 7.5% from $1.28B a quarter earlier.
Sellers outnumbered buyers: 33 funds closed out of DAWN and 32 opened new positions — a net loss of 1 holder — while 39 trimmed existing stakes and 62 added.
The largest buyer was Fidelity Investments, adding an estimated $76.2M. The largest seller was Viking Global Investors, exiting entirely with an estimated $35.6M sold.
- 164 institutional investors held Day One Biopharmaceuticals (DAWN) as of Q4 2024, down from 166 in Q3 2024.
- Funds reported $1.19B of Day One Biopharmaceuticals stock for Q4 2024, down 7.5% quarter-over-quarter.
- 32 funds opened new Day One Biopharmaceuticals positions in Q4 2024 and 33 closed out, a net change of -1 holder.
- The largest Day One Biopharmaceuticals buyer in Q4 2024 was Fidelity Investments, an estimated $76.2M added.
- The largest Day One Biopharmaceuticals seller in Q4 2024 was Viking Global Investors, an estimated $35.6M sold.
Based on aggregated 13F filings for Q4 2024.